Home > Browse Research > Life Sciences > Pharmaceuticals > Manufacturing, Packaging & Detailing

Manufacturing, Packaging & Detailing: reports

Manufacturing, Packaging & Detailing market research reports and industry analysis

Contract Research Organizations in the US - Industry Market Research Report 3/6/2013 \| published by: IBISWorld ... shorten drug or device development cycles. Furthermore, industry services have been particularly attractive to manufacturers because of the cost savings they have provided in the midst of tough economic conditions. During the next five years, ... \| read more...	$910.00
Kuwait Pharmaceuticals and Healthcare Report Q2 2013 3/6/2013 \| published by: Business Monitor International ... are obliged to pay a health insurance premium to beentitled to state-funded treatment. Kuwait is working to upgrade existing healthcare facilities and constructnew ones, such as an outpatient department at Al-Razi Hospital and the Sheikh ... \| read more...	$1,175.00
Conference Documentation: Superbugs & Superdrugs - A Focus on Antibacterials 3/4/2013 \| published by: SMI Publishing, Ltd ... market. This unique conference will present attendees with a complete view into the latest in combating multi-drug resistance, diagnostics and new focus on vaccine development for the prevention of nosocomial bacterial infections. This year’s event ... \| read more...	$788.78
China Pharmaceutical Equipment Industry Report, 2012-2015 3/1/2013 \| published by: Research in China ... showing a rapid growth trend. In line with statistics of the China Association for Pharmaceutical Equipment, in 2011 the pharmaceutical equipment industry of China achieved gross industrial output value of RMB15.84 billion, a year-on-year increase ... \| read more...	$2,000.00
Gelatin Markets in China 3/1/2013 \| published by: Asia Market Information & Development Company ... environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China ... \| read more...	$2,000.00
New Oral Anticoagulants Markets 3/1/2013 \| published by: TriMark Publications ... blood and only help prevent the formation of new blood clots. For more than 50 years and until recently, the only oral anticoagulants were vitamin K antagonists such as warfarin. Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis ... \| read more...	$3,400.00
Therapeutic Drug Monitoring Markets 3/1/2013 \| published by: TriMark Publications ... drug monitoring testing provides clinical information to optimize dosage regimes and prevent adverse reactions and lack of treatment compliance. Therapeutic Drug Monitoring Markets analyzes the therapeutic drug monitoring market and the various market segments within ... \| read more...	$3,400.00
Penicillin Markets in China 3/1/2013 \| published by: Asia Market Information & Development Company ... environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China ... \| read more...	$2,000.00
China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth 2/28/2013 \| published by: GBI Research ... Rapidly Ageing Population Provide Strong Stimulus for Growth” provides in-depth analysis of the trends, issues and challenges facing the Chinese pharmaceutical market. It details the macroeconomic environment of China, providing a background of the financial ... \| read more...	$3,500.00
Freedonia Focus on Animal Health Products: United States 2/28/2013 \| published by: Freedonia Focus Reports ... health products. Total demand is also segmented by end user in terms of animal food manufacturers, farms, veterinarians, households, and other end users. To illustrate historical trends, total demand is provided at five year intervals ... \| read more...	$600.00
Intellinews - Romania Pharmaceutical Report - February 2013 2/28/2013 \| published by: Intellinews ... statistics and comments. This sector report is ideal to keep you abreast on recent company and industry news. Written by local professionals, it is a unique market and business intelligence analysis, tailored to save time ... \| read more...	$210.00
Canada Pharmaceuticals and Healthcare Report Q2 2013 2/27/2013 \| published by: Business Monitor International ... high generic drug pricewill fall further which will ultimately benefit consumers. Headline Expenditure Projections Pharmaceuticals: CAD25.6bn (US$25.6bn) in 2012 to CAD25.8bn (US$25.5bn) in 2013; -0.4% growthin local currency terms and 0.5% growth in US dollar ... \| read more...	$1,175.00
Italy Pharmaceuticals and Healthcare Report Q2 2013 2/27/2013 \| published by: Business Monitor International ... medicines. Headline Expenditure Projections Pharmaceuticals: EUR23.53bn (US$30.25bn) in 2012 to EUR22.58bn (US$30.25bn) in 2013; -4.0% in local currency terms. Healthcare: EUR154.20bn (US$198.25bn) in 2012 to EUR156.83bn (US$210.15bn) in 2013; +1.7% growth in local currency terms. \| read more...	$1,175.00
Romania Pharmaceuticals and Healthcare Report Q2 2013 2/27/2013 \| published by: Business Monitor International ... tax will undoubtedly provide the industry with a slight boost this year. In termsof debts and timeliness of payments, the CNAS is still within its remit to reimburse drugmakers some 210days after request and almost ... \| read more...	$1,175.00
Central America Pharmaceuticals and Healthcare Report Q2 2013 2/27/2013 \| published by: Business Monitor International ... and India. We highlight that Costa Rica and Panama can be the premier countries in the region for foreigndrugmakers to expand their presence. Headline Expenditure Projections Pharmaceuticals: US$3.5bn in 2012 to US$3.7bn in 2013; +6.3% ... \| read more...	$1,175.00
Portugal Pharmaceuticals and Healthcare Report Q2 2013 2/27/2013 \| published by: Business Monitor International ... affected all areas of the market, and even sectors that might expectto rake the benefits of lower budgets, such as generic drugs, are seeing profit margins shaved. Such limitedopportunities for sales deter multinationals from investing ... \| read more...	$1,175.00
Singapore Pharmaceuticals and Healthcare Report Q2 2013 2/27/2013 \| published by: Business Monitor International ... that the innovative nature of the biomedicalsector will attract pharmaceutical firms to set up regional offices, research and development andmanufacturing bases and use it as a base from which to market products to other Asian ... \| read more...	$1,175.00
Conference Documentation: Lyophilisation: Freeze-Drying in Pharmaceuticals and Biopharmaceuticals 2/25/2013 \| published by: SMI Publishing, Ltd ... to combat the issues with the industry and enhance our existing solutions. With SMi’s first event in this sector we will be bringing KOL's from the industry together to speak on the latest topics of ... \| read more...	$788.78
PharmaPoint: Epilepsy - Current and Future Players 2/25/2013 \| published by: GlobalData ... companies in the rapidly growing Epilepsy Market. The report identifies and analyses the key companies shaping and driving the global Epilepsy market. The report provides insight into the competitive Epilepsy landscape, including new companies entering ... \| read more...	$2,995.00
Trobalt/Potiga (Epilepsy) - Forecast and Market Analysis to 2022 2/25/2013 \| published by: GlobalData ... spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both ... \| read more...	$3,495.00
Lamictal (Epilepsy) - Forecast and Market Analysis to 2022 2/25/2013 \| published by: GlobalData ... spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both ... \| read more...	$3,495.00
Lyrica (Epilepsy) - Forecast and Market Analysis to 2022 2/25/2013 \| published by: GlobalData ... spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both ... \| read more...	$3,495.00
Vimpat (Epilepsy) - Forecast and Market Analysis to 2022 2/25/2013 \| published by: GlobalData ... spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both ... \| read more...	$3,495.00
Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022 2/25/2013 \| published by: GlobalData ... spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both ... \| read more...	$3,495.00
Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022 2/25/2013 \| published by: GlobalData ... spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both ... \| read more...	$3,495.00

< prev 3 4 5 6 7 8 9 10 11 12 next >